Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanguard/Roche Claim To Have Serotonin Obesity Target Without Redux AEs

Executive Summary

Vanguard Medica has found a serotonin receptor target that has a role in controlling obesity but is not associated with the cardiovascular side effects of Redux, Vanguard CEO Robert Mansfield told the Chase H&Q Investing in Biotechnology Conference May 10 in London.

You may also be interested in...



Elan Miguard

"Approvable" letter received for frovatriptan. FDA is requesting additional data from an ongoing preclinical study involving higher-than-previous doses in mice and supplementary data from long-term pharmaceutical stability and clinical studies of the drug. Submission of the data is anticipated by the end of the third quarter. An NDA for the anti-migraine drug was submitted in January 1999 by Vanguard Medical Group, which licensed North American rights for the product to Elan

AHP Sale Of Cyanamid To BASF Will Re-Open Merger Possibilities

The sale of American Home Products' agricultural and crop sciences division Cyanamid will give the company a pharmaceutical profile that clears the way for a new round of merger discussions.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel